Insulin Delivery Clinical Trial Analysis

Summary

Global Markets Direct's "Insulin Delivery Clinical Trials Analysis" is an essential source of data and information pertaining to product clinical trials being carried out by Insulin Delivery device manufacturers, globally. The report provides exhaustive information on each clinical investigation study with coverage detailed coverage on the pipeline products these trials are being carried out for.

Scope

• The report provides analysis and review of the key clinical trials being carried out globally and across key Insulin Delivery market categories - Insulin Syringes,Reusable Insulin Pens,Disposable Insulin Pens,Traditional Insulin Pumps,Disposable Insulin Pumps,Traditional Insulin Pump Accessories
• The report covers information on each product being clinically tested with detailed coverage on the pipeline product profile, the indication it's being investigated for etc.
• The report provides an in-depth analysis of the clinical trials with information on trial phase, trial 0status, trial acronym, purpose, inclusion and exclusion criteria, description, design, intervention, investigator information, primary and secondary end-points and trial results
• The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Global Markets Direct's team of industry experts.

Reasons to Buy

• Effectively plan your Mergers and Acquisitions and partnership strategies by identifying companies with the most promising pipeline.
• Stay ahead of the information curve in the fast changing Insulin Delivery market.
• Plan in-licensing and out-licensing opportunities through review of pipeline products and technologies.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Proactively plan and execute your competitive strategies by identifying clinical trials status of the leading competitive products in pipeline.
• Stay ahead of competition by understanding the changing competitive landscape in specific geographies.

Contents

• 1 List of Tables
• 1.2 List of Figures
• 2 Insulin Delivery Clinical Trials
  • 2.1 Insulin Delivery Clinical Trial By Equipment Type
  • 2.2 Insulin Delivery Clinical Trials By Trial Phase and Trial Status
  • 2.3 Insulin Delivery Pipeline Products By Development Stage
  • 2.4 Insulin Delivery Pipeline Products By Therapy Area
  • 2.5 Insulin Delivery Pipeline Products By News Summary
• 3 Recent Developments
  • 3.1 Product News
    • 3.1.1 May 29, 2009: Study Reveals Novo Nordisk's Next Generation FlexPen Has A Significantly Lower Injection Force Than SoloStar And KwikPen
    • 3.1.2 Apr 30, 2009: Disetronic Medical Systems Inc Announces Recall Of The ACCU-CHEK Spirit Insulin Pump Due To Potential Button Failure
    • 3.1.3 Apr 20, 2009: Sanofi-Aventis Announces US Availability Of Apidra SoloSTAR
    • 3.1.4 Apr 14, 2009: Ypsomed Announces Launch Of Ypsopen In Poland
    • 3.1.5 Mar 25, 2009: Smiths Medical Announces Intent To Stop Selling Deltec Cozmo Insulin Pumps
    • 3.1.6 Mar 02, 2009: Generex To Present Oral-Lyn At International Conference On Advances In Diabetes And Insulin Therapy
    • 3.1.7 Feb 26, 2009: FDA Approves Sanofi-aventis' Apidra SoloSTAR
    • 3.1.8 Feb 11, 2009: Insulet Corporation's OmniPod System Selected As Finalist For The 2009 Edison Best New Product Awards
    • 3.1.9 Dec 23, 2008: Generex Receives Approval For Oral-lyn
    • 3.1.10 Dec 01, 2008: BD Launches 8mm BD AutoShield Pen Needle
    • 3.1.11 Sep 18, 2008: Patton Medical Devices LP Diabetes Spectrum Reports A Study Assessing The i-port Injection Port For Administration Of Insulin
    • 3.1.12 Sep 16, 2008: MannKind Reports Positive Data From A Phase 3 Clinical Study Of Technosphere Insulin In Type 1 Diabetes
    • 3.1.13 Sep 08, 2008: Novo Nordisk Launches A Next Generation Of FlexPen
    • 3.1.14 Jul 15, 2008: Medical Plastic Devices Announces Release Of PIC Insumed Precision Syringes In United States
    • 3.1.15 Mar 07, 2008: Lilly Announces Termination of AIR Insulin Program
    • 3.1.16 Feb 14, 2008: Sanofi-aventis' SoloSTAR Insulin Pen For Lantus And Apidra Receives The GOOD DESIGN Award
    • 3.1.17 Mar 28, 2007: BD Medical Announces The Launch Of The BD AutoShield Pen Needle
  • 3.2 Product Approvals
    • 3.2.1 Feb 26, 2009: FDA Approves Sanofi-aventis' Apidra SoloSTAR
    • 3.2.2 Dec 23, 2008: Generex Receives Approval For Oral-lyn
  • 3.3 Clinical Trials
    • 3.3.1 May 29, 2009: Study Reveals Novo Nordisk's Next Generation FlexPen Has A Significantly Lower Injection Force Than SoloStar And KwikPen
    • 3.3.2 Sep 18, 2008: Patton Medical Devices LP Diabetes Spectrum Reports A Study Assessing The i-port Injection Port For Administration Of Insulin
    • 3.3.3 Sep 16, 2008: MannKind Reports Positive Data From A Phase 3 Clinical Study Of Technosphere Insulin In Type 1 Diabetes
• 4 Appendix
  • 4.1 Methodology
    • 4.1.1 Coverage
    • 4.1.2 Secondary Research
    • 4.1.3 Primary Research
    • 4.1.4 Expert Panel Validation
  • 4.2 Contact Us
  • 4.3 About Global Markets Direct
  • 4.4 Disclaimer
• 1 List of Tables
  • Table 1: Insulin Delivery Clinical Trial By Equipment Type
  • Table 2: Insulin Delivery Clinical Trials By Trial Phase and Trial Status
  • Table 3: Insulin Delivery Pipeline Products By Development Stage
  • Table 4: Insulin Delivery Pipeline Products By Therapy Area
  • Table 5: Insulin Delivery Pipeline Products By News Summary
• 1.2 List of Figures
  • Figure 1: Global Markets Direct Methodology